11.04.2016 • NewsAstraZenecaDede WillamsDevelopment

Lilly, AstraZeneca Alzheimer's Trial Advances

Eli Lilly and AstraZeneca are moving into Phase 3 of their Amaranth study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor that could be a potential treatment for early Alzheimer's disease.

The Phase 3 trial, called Daybreak, will investigate the safety and efficacy of the test drug over a two-year treatment period, along with the hypothesis that it is a disease-modifying treatment. Beginning in this year’s third quarter, the companies hope to enroll about 2,200 patients with mild Alzheimer’s in 14 countries.

An independent data monitoring committee has recommended that the study continues without modification after conducting an interim safety analysis, which was not designed to review efficacy.

Under the agreement signed in 2014, Lilly will pay AstraZeneca up to $500 million in development and regulatory milestone payments. With AZD3293 moving into Phase 3, AstraZeneca will receive a milestone payment from Lilly.

The US drugmaker is leading clinical development in conjunction with British-Swedish company’s researchers,
while AstraZeneca will be responsible for manufacturing. The pharmaceutical producers will share responsibility for commercialization of the molecule as well as sharing all future costs equally for development and commercialization, in addition to net global revenue post-launch.

In Phase 1 studies AZD3293 is said to have shown lower levels of amyloid beta in the cerebro-spinal fluid of people with Alzheimer's and healthy volunteers. The companies hope that inhibiting BACE, an enzyme associated with the development of amyloid beta, will prevent the formation of amyloid plaque and eventually slow the progression of the disease.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.